A study published in Diabetes Care shows that cacaoflavonoids and soy isoflavones may improve biomarkers of cardiovascular disease (CVD) risk in postmenopausal women with type 2 diabetes.
The one-year, double-blind controlled clinical trial consisted of 93 medicated postmenopausal women with type 2 diabetes. Subjects were randomly allocated to consume 27 g/day (split dose) of flavonoid-enriched chocolate (Barry Callebaut ACTICOA chocolate containing 850 mg flavan-3-ols [90 mg epicatechin] and 100 mg of isoflavones [aglycone equivalents)]/day) or a matched placebo.
At the conclusion of this trial, the combined one-year intervention with flavan-3-ols and isoflavones resulted in an improvement in biomarkers of CVD risk in postmenopausal type 2 diabetic patients, compared to placebo. These data highlight the additional benefit of dietary flavonoids to standard drug therapy in managing CVD risk in this group of patients.